Kleanthis Xanthopoulos, Ph.D.
Russo Partners kicked off another science-heavy PR program today. This time, the focus is the promise of microRNA therapeutics — drugs that inhibit microRNAs — brought to you by a promising San Diego company called Regulus Therapeutics.
Led by a highly accomplished, well-respected scientist, Dr. Kleanthis Xanthopoulos, Regulus has taken a significant step toward independence with today’s announcement of a $20 million financing and corporate restructuring. This comes at a time that the company is advancing its development-stage compounds forward at a steady pace.
Enlisted by Dr. Xanthopoulos, with whom we worked when he was CEO of Anadys Pharmaceuticals, Russo Partners enjoyed PR success on day No. 1 by elevating the news to the top of science and business journalists’ coverage lists. The immediate results include articles in BioWorld Today, BioCentury, Xconomy and other industry-focused publications. Our media outreach also produced opportunities to connect Dr. X (as we often refer to him) to reporters with the wire services and major national media outlets, including Newsweek, Time, The Wall Street Journal, The New York Times and several broadcast outlets.
Russo Partners looks forward to working in the world of microRNA. Furthermore, we look forward to working again with a CEO with whom we’ve enjoyed a long, productive relationship.
Welcome back, Kleanthis.